Answers are grounded in this paper and cite their sources.
Although immune checkpoint blockade has become standard care in metastatic melanoma, angiogenesis inhibitors have had limited success. Now researchers have combined the two. July’s Cancer Immunology Research reported a phase I study combining ipilimumab and bevacizumab (doi:10.1016/j.ctrv.2014.06.012). Among 46 patients, the combined therapy yielded a 19.6% objective response rate and a median survival of 25.1 months—roughly twice expectations for ipilimumab alone in metastatic melanoma. And, at least by modern immunotherapy standards, patients tolerated the combination well. “A 25-month survival in a pretreated population is pretty darned impressive,” said Jeffrey Weber, M.D., Ph.D., an oncologist at Moffitt Cancer Center in Tampa, Fla. “It looked awfully promising. And certainly it’s something that needs to be pursued in a proper phase II study,” This study is under way. When Dana–Farber Cancer Institute oncologist F. Stephen Hodi Jr., M.D., conceived the phase I trial, he envisioned more than just combining two anticancer modalities—he sought synergy. Biopsy samples taken after treatment reveal a double paradox: Immunotherapy can be antiangiogenic, and antiangiogenesis can stimulate the immune system. So combining the treatments should enhance both antitumor effects. Several years ago, Hodi’s team examined posttreatment biopsy samples from patients taking ipilimumab following a cancer vaccine. The immune system specifically targeted tumor blood vessels, for still-unknown reasons. “We actually saw the blood vessels feeding the tumor deposits being destroyed by lymphocytes,” Hodi said. That observation suggested to Hodi that angiogenesis inhibitors could enhance these antitumor effects, while removing a block on immunotherapy. Over the last 20 years, evidence has accumulated that vascular endothelial growth factor (VEGF), in addition to its angiogenic role, suppresses the immune system. In 1996, David Carbone, M.D., Ph.D., then at the University of Texas Southwestern Medical Center at Dallas, reported that VEGF secreted by mouse tumor cells prevented dendritic cells from maturing, thus hampering the presentation of tumor antigen. VEGF thus blocked the antitumor immune response. Carbone’s group later showed that giving mice anti-VEGF antibodies yielded deeper and more durable immune response against the tumors, and prolonged tumor shrinkage. “It’s simplistic to think of bevacizumab as only an angiogenesis inhibitor,” said Carbone, now at Ohio State University. Hypoxia causes tumor cells, stromal cells, and normal cells to produce VEGF, with immunosuppressive effects both locally and at distant sites, including the bone marrow. VEGF is one of many immunosuppressive mechanisms that tumors hijack, however. It’s not an on–off switch like the CTLA4 and PD-1 checkpoints, Carbone said, but “it’s a player, and it modulates multiple pathways. And it might be most important in exactly the situation described in this paper, as adjunct to some of these checkpoint inhibitors, like the ipilimumab, or anti–PD-1. “It’s nice to see that [the bevacizumab–ipilimumab combination] was highly effective, a 67% disease control rate, and was not remarkably toxic,” Carbone added. Combining immunotherapy with other agents often is toxic. For example, a melanoma trial adding the U.S. Food and Drug Administration–approved targeted agent vemurafenib to ipilimumab shut down last year after five of the first seven patients showed signs of liver damage. In Hodi’s trial, 13 of 46 patients experienced severe or life-threatening adverse events. Such a rate is typical for an immunotherapy trial—especially phase I, which probes for dose-limiting toxic effects. Fortunately, only two cases of high-grade colitis, the most feared of ipilimumab’s side effects, occurred. This is about the same number one would expect from ipilimumab alone. “The one thing you worry about is intestinal perforation” from severe colitis, said David Minor, M.D., an oncologist at San Francisco’s California Pacific Center for Melanoma Research and Treatment. “If you get a perforation, then you have to remove the colon, almost always.” And since bevacizumab can cause hemorrhage, any surgery would be risky. If the phase I efficacy results hold up in larger trials, will the improvement over ipilimumab alone be due to bevacizumab’s well-known antiangiogenic effects or to enhancing the immune response? In phase I, circumstantial evidence favored the latter. Posttreatment biopsy samples showed more infiltration of effector T cells and dendritic cells across the tumor vasculature, compared with archived tumors from an old ipilimumab monotherapy trial. And patients taking the combination had higher levels of circulating T cells. They also had more antibodies against galectins (proteins involved in tumor metastasis and invasion, angiogenesis, and immunosuppression) than ipilimumab-alone patients. But such immune correlates “have been historically very hard to interpret,” Carbone said, and inconsistently linked to clinical outcomes. The combination might have done better in phase I because of a higher dose of ipilimumab. All objective responses but one were in patients taking 10mg per kilogram of body weight. But because 3mg/kg is the FDA-approved dose, that’s what investigators are using in phase II. Although 10mg was Hodi’s first choice, obtaining FDA approval for the combination at that dose would be harder. Other investigators are using bevacizumab to enhance immunotherapy. Carbone is conducting a phase II lung cancer trial adding bevacizumab to a cancer vaccine. Genentech is combining its anti–PD-L1 antibody with bevacizumab in two trials, one in solid tumors and one in renal cancer. This approach is a “totally reasonable thing to do,” Weber said. Carbone agreed: “What would excite me is adding bevacizumab to one of the PD-1 therapies.” On September 8, the FDA approved Merck’s pembrolizumab anti-PD-1 antibody for treating metastatic melanoma, and Hodi said he “would love to” combine it with bevacizumab in a melanoma trial. Jeffrey Weber, M.D., Ph.D. Meanwhile, immunotherapy combinations are moving forward. The combination of ipilimumab and the anti–PD-1 antibody nivolumab is now in phase III, after promising phase I results reported in June at the American Society of Clinical Oncology annual meeting. Minor would like to see bevacizumab added. “There’s no reason to think you would necessarily get prohibitive toxicities,” he said. Hodi is waiting for the ipilimumab–nivolumab combination, which already causes some severe autoimmune side effects, to prove itself in phase III before considering adding a third agent. [Both bevacizumab (Avastin) and ipilimumab (Yervoy) are FDA-approved drugs. Should community oncologists give the combination now, assuming that patients can afford it? “If it were the greatest thing since canned beer, perhaps,” Weber said. “[But] I wouldn’t be using this off-label, off-protocol: A, insurers aren’t going to pay for it, almost never. And B, you shouldn’t rob the investigators of the chance to prove whether it works.” Hodi agreed: “My preference would be to answer the question with a clinical trial first.” Adding bevacizumab is just one way to improve immunotherapy. An alphabet soup of other possible combinations exists. “You’ll be looking at PD-1 and [ipilimumab] with things like anti-CD137, OX40, [and] other protein checkpoint inhibitors—like Vista, Tim-3, Lag-3, BTLA, CD160, CD244. There’s a rationale for all these things,” Weber said. Cancer vaccines, kinase inhibitors, and other targeted drugs, and even chemotherapy are other possibilities. “Obviously you’ve got to prioritize,” Weber said. “But people like me will be kept in business for a long time, testing all these combinations.”
No takes yet. Share an insight, caveat, or question.
Ken Garber (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: